Want to see HK:1110 full AI Analyst Report?
Kingworld Medicines Group Ltd. (1110) Ratios
Kingworld Medicines Group Ltd. Ratios
HK:1110's free cash flow for Q2 2026 was $-50.21M. For the 2026 fiscal year, HK:1110's free cash flow was decreased by $-9.93M and operating cash flow was $-40.28M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.09 | 1.18 | 1.27 | 1.15 | 1.35 |
| Quick Ratio | 0.85 | 0.95 | 1.02 | 1.00 | 1.13 |
| Cash Ratio | 0.47 | 0.46 | 0.37 | 0.45 | 0.40 |
| Solvency Ratio | 0.05 | 0.07 | 0.09 | 0.11 | 0.13 |
| Operating Cash Flow Ratio | 0.15 | 0.26 | 0.09 | 0.34 | 0.17 |
| Short-Term Operating Cash Flow Coverage | 0.32 | 0.60 | 0.22 | 0.69 | 0.35 |
| Net Current Asset Value | $ -139.85M | $ -102.27M | $ -49.68M | $ 55.17M | $ 146.46M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.30 | 0.28 | 0.26 | 0.23 | 0.20 |
| Debt-to-Equity Ratio | 0.70 | 0.63 | 0.57 | 0.47 | 0.39 |
| Debt-to-Capital Ratio | 0.41 | 0.39 | 0.36 | 0.32 | 0.28 |
| Long-Term Debt-to-Capital Ratio | 0.19 | 0.20 | 0.20 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.34 | 2.21 | 2.16 | 2.05 | 1.97 |
| Debt Service Coverage Ratio | 0.23 | 0.33 | 0.46 | 0.33 | 0.40 |
| Interest Coverage Ratio | 4.50 | 6.75 | 8.40 | 5.88 | 6.13 |
| Debt to Market Cap | 1.51 | 1.57 | 0.98 | 0.60 | 0.61 |
| Interest Debt Per Share | 0.76 | 0.72 | 0.62 | 0.50 | 0.41 |
| Net Debt to EBITDA | 2.05 | 1.66 | 1.44 | 0.41 | 0.44 |
| Profitability Margins | |||||
| Gross Profit Margin | 27.02% | 25.49% | 26.02% | 28.99% | 31.11% |
| EBIT Margin | 6.18% | 8.54% | 9.77% | 8.34% | 9.58% |
| EBITDA Margin | 9.02% | 9.47% | 11.63% | 12.33% | 13.69% |
| Operating Profit Margin | 6.89% | 8.45% | 8.97% | 7.54% | 8.52% |
| Pretax Profit Margin | 6.26% | 9.00% | 8.70% | 7.06% | 8.19% |
| Net Profit Margin | 1.23% | 3.92% | 3.53% | 2.37% | 3.58% |
| Continuous Operations Profit Margin | 4.24% | 7.02% | 5.71% | 4.55% | 6.04% |
| Net Income Per EBT | 19.64% | 43.51% | 40.58% | 33.65% | 43.67% |
| EBT Per EBIT | 90.93% | 106.48% | 96.98% | 93.56% | 96.14% |
| Return on Assets (ROA) | 0.78% | 2.94% | 2.85% | 1.80% | 2.50% |
| Return on Equity (ROE) | 1.83% | 6.50% | 6.15% | 3.69% | 4.91% |
| Return on Capital Employed (ROCE) | 7.20% | 9.96% | 11.07% | 10.01% | 9.76% |
| Return on Invested Capital (ROIC) | 3.72% | 6.18% | 5.92% | 4.65% | 5.45% |
| Return on Tangible Assets | 0.83% | 3.14% | 3.06% | 1.94% | 2.73% |
| Earnings Yield | 4.12% | 16.89% | 10.93% | 4.99% | 8.08% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.45 | 6.73 | 7.07 | 5.23 | 3.56 |
| Payables Turnover | 4.11 | 4.94 | 5.37 | 4.90 | 5.50 |
| Inventory Turnover | 5.02 | 6.58 | 6.78 | 8.02 | 5.47 |
| Fixed Asset Turnover | 2.04 | 2.50 | 2.80 | 3.19 | 4.04 |
| Asset Turnover | 0.64 | 0.75 | 0.81 | 0.76 | 0.70 |
| Working Capital Turnover Ratio | 12.98 | 9.74 | 10.39 | 7.70 | 5.21 |
| Cash Conversion Cycle | 65.91 | 35.94 | 37.42 | 40.82 | 102.85 |
| Days of Sales Outstanding | 81.95 | 54.26 | 51.61 | 69.81 | 102.44 |
| Days of Inventory Outstanding | 72.70 | 55.50 | 53.80 | 45.49 | 66.74 |
| Days of Payables Outstanding | 88.74 | 73.82 | 68.00 | 74.49 | 66.34 |
| Operating Cycle | 154.65 | 109.75 | 105.42 | 115.31 | 169.18 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.14 | 0.24 | 0.07 | 0.31 | 0.13 |
| Free Cash Flow Per Share | 0.09 | 0.16 | -0.11 | 0.15 | 0.04 |
| Dividend Paid and CapEx Coverage Ratio | 1.77 | 2.23 | 0.35 | 1.76 | 1.32 |
| Capital Expenditure Coverage Ratio | 2.85 | 3.31 | 0.40 | 2.01 | 1.39 |
| Operating Cash Flow Coverage Ratio | 0.19 | 0.34 | 0.12 | 0.64 | 0.34 |
| Operating Cash Flow to Sales Ratio | 0.09 | 0.13 | 0.04 | 0.19 | 0.10 |
| Free Cash Flow Yield | 20.06% | 38.49% | -18.15% | 20.56% | 6.10% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 24.33 | 5.92 | 9.15 | 20.02 | 12.38 |
| Price-to-Sales (P/S) Ratio | 0.30 | 0.23 | 0.32 | 0.48 | 0.44 |
| Price-to-Book (P/B) Ratio | 0.44 | 0.38 | 0.56 | 0.74 | 0.61 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 4.99 | 2.60 | -5.51 | 4.86 | 16.41 |
| Price-to-Operating Cash Flow Ratio | 3.24 | 1.81 | 8.24 | 2.44 | 4.62 |
| Price-to-Earnings Growth (PEG) Ratio | -0.33 | 0.49 | 0.13 | -0.80 | 0.08 |
| Enterprise Value Multiple | 5.36 | 4.11 | 4.22 | 4.27 | 3.68 |
| Enterprise Value | 443.30M | 413.25M | 529.20M | 503.89M | 426.42M |
| EV to EBITDA | 5.36 | 4.11 | 4.22 | 4.27 | 3.68 |
| EV to Sales | 0.48 | 0.39 | 0.49 | 0.53 | 0.50 |
| EV to Free Cash Flow | 8.07 | 4.36 | -8.37 | 5.38 | 18.64 |
| EV to Operating Cash Flow | 5.24 | 3.04 | 12.52 | 2.70 | 5.25 |
| Tangible Book Value Per Share | 1.02 | 1.07 | 1.03 | 0.99 | 1.02 |
| Shareholders’ Equity Per Share | 1.05 | 1.11 | 1.05 | 1.01 | 1.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.32 | 0.22 | 0.34 | 0.36 | 0.26 |
| Revenue Per Share | 1.57 | 1.84 | 1.82 | 1.58 | 1.40 |
| Net Income Per Share | 0.02 | 0.07 | 0.06 | 0.04 | 0.05 |
| Tax Burden | 0.20 | 0.44 | 0.41 | 0.34 | 0.44 |
| Interest Burden | 1.01 | 1.05 | 0.89 | 0.85 | 0.85 |
| Research & Development to Revenue | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| SG&A to Revenue | 0.19 | 0.18 | 0.11 | 0.11 | 0.11 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.47 | 1.42 | 1.11 | 2.76 | 1.17 |
Currency in CNY
